Literature DB >> 18637112

The use of complementary therapy by men with prostate cancer in the UK.

S Wilkinson1, S Farrelly, J Low, A Chakraborty, R Williams, S Wilkinson1.   

Abstract

The study aims were to determine the use of complementary therapies (CT) by men with prostate cancer, and to explore factors influencing CT use and attitudes toward CT use. A cross-sectional survey design was used in which a postal questionnaire was mailed to an eligible sample of 405 patients with prostate cancer receiving outpatient treatment in a London teaching hospital. The primary outcomes were the prevalence of CT use and the relationship between CT use and mental health status. Two hundred and ninety-four patients (73%) responded, of whom 25% were using CT. The most frequently used CTs were vitamins, low-fat diets, lycopene and green tea. Multivariate analyses revealed no differences in mental health scores between CT users and non-users. CT users were younger (OR 0.93, 95% CI 0.89-0.97) and were more likely to be receiving conservative management in the form of 'active surveillance' (OR 5.23, 95% CI 1.78-15.41) compared with non-users. Over half of the participants (55%) wanted to learn more about CT. Forty-three per cent of CT users had not informed any doctor about their CT use. Clinicians need to be aware of the prevalence of CT use amongst patients with prostate cancer, considering the potential harm that could be caused by interactions with conventional treatments.

Entities:  

Mesh:

Year:  2008        PMID: 18637112     DOI: 10.1111/j.1365-2354.2007.00904.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  9 in total

1.  Complementary and alternative medicine use among newly diagnosed prostate cancer patients.

Authors:  Cara L McDermott; David K Blough; Catherine R Fedorenko; Neeraj K Arora; Steven B Zeliadt; Megan E Fairweather; Ingrid Oakley-Girvan; Stephen K Van Den Eeden; Scott D Ramsey
Journal:  Support Care Cancer       Date:  2010-12-01       Impact factor: 3.603

2.  Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer.

Authors:  Scott D Ramsey; Steven B Zeliadt; David K Blough; Catherine R Fedorenko; Megan E Fairweather; Cara L McDermott; David F Penson; Stephen K Van Den Eeden; Ann S Hamilton; Neeraj K Arora
Journal:  Urology       Date:  2012-05       Impact factor: 2.649

Review 3.  Prevalence of use of complementary and alternative medicine (CAM) by patients/consumers in the UK: systematic review of surveys.

Authors:  Paul Posadzki; Leala K Watson; Amani Alotaibi; Edzard Ernst
Journal:  Clin Med (Lond)       Date:  2013-04       Impact factor: 2.659

Review 4.  Lycopene for the prevention of prostate cancer.

Authors:  Dragan Ilic; Kristian M Forbes; Craig Hassed
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

5.  Use of Chinese medicine by cancer patients: a review of surveys.

Authors:  Bridget Carmady; Caroline A Smith
Journal:  Chin Med       Date:  2011-06-09       Impact factor: 5.455

6.  Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors.

Authors:  Sam Egger; Suzanne Hughes; David P Smith; Suzanne Chambers; Clare Kahn; Annette Moxey; Dianne L O'Connell
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

7.  Lycopene and cognitive function.

Authors:  Kristi M Crowe-White; Tinsley A Phillips; Amy C Ellis
Journal:  J Nutr Sci       Date:  2019-05-29

8.  Complementary and Alternative Medicine Use among Norwegian Cancer Survivors: Gender-Specific Prevalence and Associations for Use.

Authors:  Agnete E Kristoffersen; Arne J Norheim; Vinjar M Fønnebø
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-28       Impact factor: 2.629

9.  Factors associated with the use of diet and the use of exercise for prostate cancer by long-term survivors.

Authors:  Suzanne Hughes; Sam Egger; Chelsea Carle; David P Smith; Suzanne Chambers; Clare Kahn; Cristina M Caperchione; Annette Moxey; Dianne L O'Connell
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.